Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Eur Rev Med Pharmacol Sci ; 28(7): 2929-2942, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38639530

RESUMO

Human immunodeficiency virus (HIV) infection has historically been related to the development of specific cancers, some of which are so closely linked to the infection, such as Kaposi's Sarcoma (KS), that they have earned the name Acquired Immuno-Deficiency Syndrome (AIDS)-defining cancers (ADCs). While the development of antiretroviral therapy (ART) has decreased the incidence of AIDS-defining cancers, the resulting aging of people living with HIV (PLWH) highlighted an increased occurrence of other forms of cancer. At the "Gaetano Martino" hospital in Messina, we developed a multidisciplinary approach by creating a bridge between the Oncology Unit and the Infectious Diseases Unit to carry out screening and a more rapid diagnostic and therapeutic journey for cancers in PLWH. The goal is to improve the diagnosis of various types of cancer by involving other professionals, such as gastroenterologists and gynecologists, to ensure faster access to treatment and, therefore, a greater chance of survival. In addition, our multidisciplinary approach has also included vaccine screening, offered by the "Gaetano Martino" hospital and useful for preventing the development of specific forms of cancer in the entire population and particularly in PLWH.


Assuntos
Síndrome da Imunodeficiência Adquirida , Infecções por HIV , Neoplasias , Sarcoma de Kaposi , Humanos , Detecção Precoce de Câncer , Fatores de Risco , Infecções por HIV/complicações , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Sarcoma de Kaposi/epidemiologia , Neoplasias/diagnóstico , Neoplasias/epidemiologia , Hospitais
2.
Eur Rev Med Pharmacol Sci ; 26(19): 7285-7289, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-36263540

RESUMO

OBJECTIVE: On March 11, 2020, the World Health Organization (WHO) has declared the novel coronavirus (COVID-19) outbreak as a global pandemic. COVID-19 pandemic has impacted health services, including immunization programs, with a consequent reduction in vaccination coverage in those categories for which the prevention of vaccine-preventable diseases is strongly recommended. SUBJECTS AND METHODS: We conducted a retrospective cross-sectional study on the general population and on PLWHs, comparing anti-human papillomavirus (HPV) vaccination coverage data in 2019, before COVID-19 pandemic, and the 2020 data, after the announcement of the pandemic state and the lockdown and the implementation of restrictive measures to contain the contagion. RESULTS: Compared to 2019, 2020 data show a 42% reduction in HPV vaccine coverage in the general population and 36% in PLWHs. The greatest reduction in anti-HPV vaccination coverage occurred during periods of greatest restriction and mainly concerned the general population. CONCLUSIONS: The prevention of vaccine-preventable diseases remains essential. Above all, it is essential to increase and recover the anti-HPV vaccine coverage, in consideration of the data that show its preventive oncological efficacy.


Assuntos
COVID-19 , Infecções por Papillomavirus , Vacinas contra Papillomavirus , Doenças Preveníveis por Vacina , Humanos , Cobertura Vacinal , COVID-19/prevenção & controle , Pandemias/prevenção & controle , Estudos Transversais , Estudos Retrospectivos , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/prevenção & controle , Controle de Doenças Transmissíveis , Vacinas contra Papillomavirus/uso terapêutico , Vacinação
3.
Eur Rev Med Pharmacol Sci ; 26(13): 4863-4871, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35856378

RESUMO

OBJECTIVE: Human brucellosis is a zoonosis with an extremely wide spectrum of clinical manifestations. Focal splenic involvement is very uncommon, particularly in the pediatric age group, during the illness' acute phase. CASE REPORT: A 4-year-old boy, already receiving third-generation cephalosporin treatment, was transferred from a local hospital to the University Pediatric Department for fever, anemia, increased inflammation index, and multiple, hyper-echogenic splenic lesions on abdominal ultrasound. Initial diagnostic laboratory investigations for Brucella infection, including the Widal-Wright test, were found to be negative. However, further diagnostic laboratory analysis using the chemiluminescent immunoassay was positive for Brucella IgM antibodies. Treatment with rifampicin at a dose of 150 mg/Kg/twice daily and co-trimethoprim at a dose of 80 mg/Kg/twice daily was started and continued for 7 weeks. IgM antibodies were undetectable after 2 weeks of treatment, and after 6 weeks of treatment, abdominal ultrasound documented a reduction of the diameter of the major splenic infiltrate from 1 to 0.5 cm. At 3 and 5 months of follow-up, re-evaluation of the abdominal lesions displayed complete resolution of the splenic lesions and a complete clinical recovery. CONCLUSIONS: The present case and a literature review are presented in this study since a standard diagnostic laboratory evaluation for brucellosis may miss the diagnosis, and in suspected cases, the laboratory analysis should be extended. Splenic abscesses are known to be rare in brucellosis, but the diagnosis should be considered in children with severe focal lesions, as specific antibiotic treatment may result in complete clinical recovery.


Assuntos
Brucelose , Esplenopatias , Abscesso , Antibacterianos/uso terapêutico , Brucelose/diagnóstico , Brucelose/tratamento farmacológico , Brucelose/patologia , Criança , Pré-Escolar , Humanos , Imunoglobulina M , Masculino , Esplenopatias/diagnóstico por imagem , Esplenopatias/tratamento farmacológico
4.
Eur Rev Med Pharmacol Sci ; 24(14): 7889-7904, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32744718

RESUMO

OBJECTIVE: In late December 2019 in Wuhan (China), Health Commission reported a cluster of pneumonia cases of unknown etiology, subsequently isolated and named Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2). In this review, the main transmission routes and causes of mortality associated with COVID-19 were investigated. MATERIAL AND METHODS: A review was carried out to recognize relevant research available until 10 April 2020. RESULTS: The main transmission routes of COVID-19 have been the following: animal to human and human-to-human pathways, namely: respiratory transmission; oro-fecal transmission; air, surface-human transmission. Transmission from asymptomatic persons, healthcare transmission, and interfamily transmission have been well documented. CONCLUSIONS: SARS-CoV-2 possesses powerful pathogenicity and transmissibility. It is presumed to spread primarily via respiratory droplets and close contact. The most probable transmission pathway is definitely the inter-human one. Asymptomatic patients seem to play a crucial role in spreading the infection. Because of COVID-19 infection pandemic potential, careful surveillance is essential to monitor its future host adaptation, viral evolution, infectivity, transmissibility, and pathogenicity in order to gain an effective vaccine and flock immunity and reduce mortality as soon and as much as it is possible.


Assuntos
Infecções por Coronavirus/transmissão , Pneumonia Viral/transmissão , Animais , Doenças Assintomáticas , Betacoronavirus/isolamento & purificação , COVID-19 , Infecções por Coronavirus/patologia , Infecções por Coronavirus/virologia , Fezes/virologia , Humanos , Transmissão Vertical de Doenças Infecciosas , Pandemias , Pneumonia Viral/patologia , Pneumonia Viral/virologia , SARS-CoV-2 , Escarro/virologia
6.
Eur Rev Med Pharmacol Sci ; 24(7): 3849-3875, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32329861

RESUMO

The increasing incidence of chronic pathologies and especially non-AIDS defining cancers, such as lung cancer, hepatocellular carcinoma, breast cancer, colorectal cancer, prostate cancer, and Hodgkin's lymphoma after the introduction of combined antiretroviral therapy requires the infectious diseases specialist to know how and when to suspect and diagnose cancer in people living with HIV. The aim of this review is to provide updated studies and information about non-AIDS defining cancers and their management in PLWH sheading a light on possible futures scenarios.


Assuntos
Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Neoplasias/diagnóstico , Neoplasias/terapia , Humanos , Neoplasias/complicações
7.
Eur Rev Med Pharmacol Sci ; 23(17): 7488-7497, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31539137

RESUMO

Kaposi's Sarcoma (KS) is an angiogenic tumor involving skin, mucosa and splanchnic organs. It is caused by Human Herpes Virus 8 (HHV8), when in the presence of other cofactors, such as an immune dysregulation. KS is particularly frequent in HIV-infected individuals. The major goals of treatment are to prevent disease progression, to reduce tumor and edema, to avoid organ compromise, and to relieve psychological stress. The importance and the high cancer risk offered by this co-infection, together with the spread of both these viruses, and the fact that angiogenesis is such an important characteristic of KS led to a lively interest in finding a definitive therapy. Most of the ongoing studies are focused on finding an application of old drugs in KS. Unfortunately, given the number of studies with different targets, it seems we are still far from completely understanding this disease and obtaining a "cure" which could be effective and safe for everyone. Further studies will hopefully offer new and definitive solutions.


Assuntos
Neovascularização Patológica/virologia , Sarcoma de Kaposi/tratamento farmacológico , Antivirais/farmacologia , Antivirais/uso terapêutico , Ensaios Clínicos como Assunto , Gerenciamento Clínico , Tratamento Farmacológico , Herpesvirus Humano 8/efeitos dos fármacos , Herpesvirus Humano 8/patogenicidade , Humanos , Neovascularização Patológica/tratamento farmacológico , Sarcoma de Kaposi/psicologia , Resultado do Tratamento
8.
Eur Rev Med Pharmacol Sci ; 23(16): 7163-7182, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31486519

RESUMO

Vaccinations are the most effective preventive methods against infectious diseases and represent one of the most relevant successes of medicine. Vaccine development is constantly evolving; therefore, the number of vaccine candidates is progressively increasing. However, most of new potential vaccines are characterized by a lower immunogenicity, with the inability to stimulate powerful and long-lasting immune responses. Hence, to get modern and effective vaccines, we need adjuvants and innovative delivery systems that increase their immunogenicity. The use of nanotechnology in vaccinology is providing the opportunity to contrast these difficulties and develop effective vaccines. Particularly, nanoparticles used as vehicles of vaccine components, are able to increase the host's immune responses and, due to their size, to reach specific cellular districts. To date, a certain number of nanovaccines has been approved for human health and many are studied in clinical or pre-clinical trials. There are several types of nanoparticles considered as possible delivers of vaccine antigens. These nanoparticles-based synthetic delivery systems, in the size range of 20-200 nm, protect antigen from degradation, enhance its presentation and facilitate its uptake by professional antigen-presenting cells. Virus-like particles, self-assembled proteins, micelles, liposomes, inorganic nanoparticles, and polymers are the most studied of these systems. In this review, we provide a general overview of different types, methods of synthesis, characterizations, properties and applications of nanoparticles in vaccine production.


Assuntos
Sistemas de Liberação de Medicamentos , Nanopartículas/química , Vacinas/química , Animais , Humanos , Tamanho da Partícula , Vacinas/síntese química
9.
J Prev Med Hyg ; 60(2): E84-E92, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31312737

RESUMO

INTRODUCTION: STIs are a serious public health problem. Worldwide, 500 million people a year acquire a STI, and young are the most affected. METHODS: This study was conducted administering an anonymous questionnaire to 1228 Sicilian students of high school and university. RESULTS: The students had variable understanding of STIs and their complications. The results demonstrate an extreme variability in the knowledge of STIs. Multiple linear regression showed that sexual health knowledge was associated with age and sexual orientation. CONCLUSIONS: Our results show that knowledge of STIs is poor and inadequate. This finding can put students at risk of STIs.


Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Infecções Sexualmente Transmissíveis/psicologia , Estudantes/psicologia , Sexo sem Proteção/estatística & dados numéricos , Adolescente , Adulto , Fatores Etários , Feminino , Humanos , Itália , Masculino , Instituições Acadêmicas , Comportamento Sexual/psicologia , Comportamento Sexual/estatística & dados numéricos , Estudantes/estatística & dados numéricos , Inquéritos e Questionários , Universidades , Sexo sem Proteção/psicologia , Adulto Jovem
10.
Eur Rev Med Pharmacol Sci ; 23(3): 1158-1164, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30779085

RESUMO

With the introduction of HAART, the life expectancy of the patients infected with HIV almost approached that of the general population. The incidence of certain HIV-Associated cancers as Kaposi Sarcoma (KS) and Non-Hodgkin Lymphoma (NHL) decreased, while an increase in Non-AIDS-Defining cancers (NADCs) has been documented. HIV infection is a risk factor for numerous cancers in PLWH. Breast cancer is the most common cancer worldwide among all women. The association between HIV infection and breast cancer has not been thoroughly investigated: when compared to the general population, people living with HIV/AIDS (PLWHA) have a similar or slightly lower risk of breast cancer. Screening tests are essential weapons to fight cancer burden and more effective therapeutic and preventive strategies are needed, especially among PLWHA. Further and more comprehensive studies are needed to better characterize breast cancer among PLWH.


Assuntos
Neoplasias da Mama/epidemiologia , Infecções por HIV/epidemiologia , Síndrome da Imunodeficiência Adquirida/epidemiologia , Síndrome da Imunodeficiência Adquirida/virologia , Terapia Antirretroviral de Alta Atividade , Neoplasias da Mama/virologia , Feminino , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Humanos , Incidência , Linfoma não Hodgkin/epidemiologia , Linfoma não Hodgkin/virologia , Fatores de Risco , Sarcoma de Kaposi/epidemiologia , Sarcoma de Kaposi/virologia
11.
Eur Rev Med Pharmacol Sci ; 23(3): 1266-1278, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30779096

RESUMO

Healthcare-associated infections (HAIs) are one of the most relevant public health problems worldwide. The role of the hospital environment as a reservoir of pathogens causing HAIs is still debated. These pathogens are common in several hospital environments, where they are able to persist from hours to months and their circulation is favored by healthcare workers (HCWs). Hospital surfaces at close contact with patients such as bed bars and header, bedside table, taps, and handles in wards ("high-touched surfaces"), are considered easily contaminable and at risk to transfer pathogens to patients. However, some studies showed the possible role played by "non-classical" surfaces such as healthcare workers' (HCWs) mobile phones and personal computers as well as oxygen humidifiers and protective lead garments used in operating rooms. HCWs' hands play a fundamental role in patient-to-patient transmission by touching contaminated surfaces or patients during care activities. The aim of this review is to evaluate the role of the hospital environment in the transmission of nosocomial pathogens, focusing on single pathogens causing HAIs and the importance of hospital surfaces as reservoirs.


Assuntos
Infecção Hospitalar/etiologia , Transmissão de Doença Infecciosa/prevenção & controle , Microbiologia Ambiental/normas , Hospitais/normas , Candida albicans/isolamento & purificação , Infecção Hospitalar/microbiologia , Infecção Hospitalar/virologia , Bactérias Gram-Negativas/isolamento & purificação , Bactérias Gram-Positivas/isolamento & purificação , Humanos , Norovirus/isolamento & purificação
12.
Eur Rev Med Pharmacol Sci ; 21(24): 5859-5867, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-29272025

RESUMO

The efficacy of the current HIV therapy has led to increased survival and prolongation of the average life expectancy of people living with HIV (PLWH), as well as the emergence of comorbidities and non-AIDS related cancer. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Current evidence suggests that HCC is an important cause of morbidity and mortality in HIV infected patients. In fact, HCC prevalence rate is indeed higher with respect to the general population average. In this paper, we review the diagnostic and therapeutic management of Hepatitis C-related hepatocellular carcinoma in HCV-HIV co-infected patients. Several therapeutic options are available depending on several factors as HCC stage, liver functions, comorbidities and they have been divided into three groups: potentially curative, proven effective but not curative, and unproven or ineffective therapy. In HIV-infected patients, surgical options are preferred compared to non-surgical therapies. Further studies, especially multicenter ones, are needed in order to define the most appropriate, evidence-based therapeutic approach to PLWH suffering from HCC. It also appears necessary to develop appropriate care guidelines for PLWH.


Assuntos
Carcinoma Hepatocelular/terapia , Coinfecção/complicações , Infecções por HIV/complicações , Hepatite C/complicações , Neoplasias Hepáticas/terapia , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/etiologia , Comorbidade , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/etiologia
13.
Eur Rev Med Pharmacol Sci ; 21(24): 5868-5869, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-29272026

RESUMO

Kaposi's Sarcoma (KS) is a multicentric angioproliferative cancer of endothelial cells (ECs) caused by Human Herpesvirus 8 (HHV8) characterized by clinical heterogeneity depending on the host immune conditions. Despite its incidence has dramatically decreased in developed countries after the introduction of Highly Active Antiretroviral Therapy (HAART), KS remains the most frequent tumor in HIV-infected patients worldwide. Clinical presentation varies from an indolent slowly progressive behavior, generally limited to the skin, to an aggressive and rapidly progressing disease. In more than 50% of cases, the skin lesions are often associated with a more or less important visceral involvement, particularly to the oral cavity and the gastrointestinal tract that are involved in 35% and 40% of cases respectively. A large number of treatments can be used both as local and as systemic therapy. Particularly, HAART represents the first treatment in patients with moderate lesions limited to skin, and it can be sufficient to reduce significantly the size of lesions and, often, the complete disappear in 35% of cases after 3-9 months of treatment. In case of a rapidly progressive disease with extensive cutaneous and/or visceral involvement systemic drugs are used such as the liposomal anthracyclines pegylated liposomal doxorubicin (PLD) and daunorubicin citrate liposome (DNX), the combined treatment adriamycin-bleomycin-vincristine (ABV) and bleomycin-vincristine (BV), Paclitaxel and Interferon-alfa. In patients with limited skin localization, the local treatment can play an important role. Local medical therapy is based on the use of alitretinoin, antineoplastic drugs vincristine, vinblastine and bleomycin and Sodium Tetradecyl Sulfate (STS). In addition to medical therapy, physical treatment, such as cryotherapy and radiotherapy, are also commonly used.


Assuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/complicações , Sarcoma de Kaposi/terapia , Antineoplásicos/uso terapêutico , Infecções por HIV/tratamento farmacológico , Humanos , Sarcoma de Kaposi/epidemiologia , Sarcoma de Kaposi/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...